Clonazepam Orally Disintegrating Tablets Recall

On Nov. 19, 2024, Endo Pharmaceuticals, the parent company of Par Pharmaceuticals, notified the FDA of an expansion of its voluntary recall of Clonazepam Orally Disintegrating Tablets due to potential mislabeling of carton strength by a third-party packager. Although the blister strips and tablets inside reflect the correct strength, some outer cartons may be printed with incorrect strength and the National Drug Code (NDC). Clonazepam is a benzodiazepine approved to treat seizures and panic disorder. Inadvertently taking higher doses of clonazepam can cause serious risks like sedation, confusion and dizziness. There's also a significant risk of life-threatening respiratory depression, especially in those with lung conditions, near maximum doses or taking other depressants. For more information on this recall, see here.